Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.